Perinatal Pharmacology: Individualized Neonatal Therapy [Aranda; Fanos; van den Anker - Hygeia]

calcActive())">
- ISBN/EAN
- 9788890651434
- Editore
- Hygeia Press
- Collana
- Systems Medicine
- Formato
- Cartonato
- Anno
- 2012
- Pagine
- 352
Disponibile
76,50 €
90,00 €
The origin of this book lies on the awareness that we have to do more for identifying unmet needs and improving a tailor-made treatment for each newborn.
After a large introduction on developmental pharmacology, this book analyses in detail new advances on antibiotics (aminoglycosides), antifungals, antivirals (CMV, RSV, HIV), analgosedatives, steroids, caffeine, and cardiovascular drugs. An updated pharmacologic treatment of respiratory diseases (respiratory distress syndrome, meconium aspiration syndrome, chronic lung disease, persistent pulmonary hypertension) is presented, as well as for persistent patent ductus arteriosus and retinopathy of prematurity. Finally, neuroprotection is considered, with special emphasis on antioxidants and melatonin.
A special part is devoted to drug-induced renal toxicity and liver toxicity and completes the volume, also quoting the so-called ‘-omics‘ sciences such as genomics and metabolomics.
The topics are covered by international experts in the field and the subtle red line that links all the chapters together is the perspective of individualized treatments to reach our ultimate goal: the right therapy for each newborn without any side effects.
Maggiori Informazioni
Autore | Aranda Jacob V.; Fanos Vassilios; van den Anker John N. |
---|---|
Editore | Hygeia Press |
Anno | 2012 |
Tipologia | Libro |
Collana | Systems Medicine |
Lingua | Inglese |
Indice | 1. Developmental pharmacology John N. van den Anker, Natella Y. Rakhmanina, Karel Allegaert Drug absorption • Drug distribution • Drug metabolism • Phase I enzymes • Drug excretion • Other factors influencing the absorption, distribution, metabolism and excretion of drugs in neonates and young infants • Pharmacogenomics: impact for pediatric populations • Developmental pharmacodynamics • Conclusions • References 2. Drug-induced liver injury in neonates: a developmental approach Gavino Faa, Daniela Fanni, Clara Gerosa, Sonia Nemolato, Yukio Gibo, Massimo Castagnola, Vassilios Fanos Pharmacokinetics in neonates • Drug-induced liver injury in neonates • Liver disease due to widely utilized drugs in newborns • Conclusions and future challenges • References 3. Influence of prenatal drug treatments on kidney function during fetal and neonatal life Laura Cuzzolin, Vassilios Fanos Pathophysiological mechanisms and renal syndromes • Prenatal exposure to drugs • Conclusions • References 4. Excipients in neonatal drug formulations: friend and foe? Roosmarijn De Cock, Catherijne Knibbe, Karel Allegaert About the compounds we routinely administer, but never prescribe • The STEP database • The ESNEE research initiative • The Leuven propylene glycol research project to illustrate feasibility and limitations • Perspectives • References 5. Pharmacotoxic effects of aminoglycosides and loud environmental noise: an overlooked risk for hearing loss in preterm infants Amir Lahav, Emily Zimmerman The prevalence of hearing loss in preterm neonates • From the protected environment of the womb to the ototoxic environment in the neonatal intensive care unit • Aminoglycosides-induced ototoxicity • Synergistic ototoxicity induced by aminoglycoside and noise exposure • Implications for clinical care • References 6. Clinical pharmacology of analgosedatives in neonates: between the hammer and the anvil? Karel Allegaert, John N. van den Anker On the relevance of (in)adequate analgesia in neonates • Clinical pharmacology of analgesics: from pharmacokinetics towards pharmacodynamics • New compounds: new tools or new toys? • Clinical practice: between the hammer and the anvil? • References 7. New treatments of persistent pulmonary hypertension of the newborn Nicoletta Iacovidou, Aggeliki Syggelou, Spyros Kloudas, Theodoros Xanthos Definitions • Pulmonary vasculature physiology – Pathophysiology of PPHN • Etiology of PPHN – Classification – Predisposing factors • Diagnosis of PPHN • Management of PPHN • References 8. Inotropic and vasopressor drugs in the newborn Hercília Guimarães, Gustavo Rocha, Paulo Soares, Henrique Soares, Maria Beatriz Guedes Inotropic agents • Epinephrine • Norepinephrine • Dopamine • Dobutamine • Isoproterenol • Milrinone • Levosimendan • References 9. Role of vasopressin and terlipressin in newborns and infants with hypotension and shock Paolo Biban, Davide Silvagni Biology of endogenous vasopressin • Role of endogenous vasopressin in shock • Pharmacology of vasopressin and terlipressin • Exogenous vasopressin and terlipressin in neonatal and pediatric shock • Safety and adverse effects of vasopressin and terlipressin • Conclusions • References 10. Pharmacological treatment of patent ductus arteriosus: the last days of indomethacin? Bart Van Overmeire Indomethacin • Ibuprofen, the preferred drug? • Gastrointestinal effects of NSAIDs • Renal adverse effects of NSAIDs • Pulmonary hypertension • Bilirubin and ibuprofen • Appropriate NSAIDs dosing • Adapted ibuprofen dosing • Oral administration • Paracetamol? • Conclusion • References 11. The role of caffeine in neonatology Pier Paolo Bassareo, Vassilios Fanos, Giuseppe Mercuro Caffeine: short-term effects • Caffeine: long-term effects • Conclusions • References 12. Pulmonary surfactant in newborn infants Virgilio P. Carnielli, Stefano Nobile, Paola E. Cogo Background and history • Composition and pharmacodynamics • Methods for pharmacokinetic studies • Surfactant therapy • References 13. Meconium aspiration syndrome: do we know the treatment? Murat Yurdakök Pathophysiology of meconium aspiration syndrome • Prophylaxis of meconium aspiration • Management of infants with meconium aspiration • Conclusions • References 14. Treatment of chronic lung disease Fabio Mosca, Valentina Polimeni, Francesca Ciuffini, Massimo Agosti, Monica Fumagalli, Mariarosa Colnaghi Caffeine • Diuretics • Postnatal corticosteroids • Surfactant • Bronchodilators • Inhaled nitric oxide • Pulmonary vasodilators • Anti-oxidants • Stem cells • Conclusion • References 15. Postnatal steroids for the prevention and treatment of bronchopulmonary dysplasia Eren Özek Postnatal corticosteroids for bronchopulmonary dysplasia • Background • Current evidence of postnatal steroid use • Choice of glucocorticoids • Timing, dosage and duration of corticosteroids • Other systemic or inhaled glucocorticoids • Summary of current evidence based recommendations • References 16. Molecular and clinical pharmacology of retinopathy of prematurity Kay D. Beharry, Jacob V. Aranda, Daniel Canal-Tristancho, Gloria B. Valencia, Douglas R. Lazarro Epidemiology and clinical considerations • Pharmacologic interventions in ROP • Caffeine • NSAIDs and COX blockade in ROP • Antioxidant use in ROP • Long chain polyunsaturated fatty acids (LCPUFA) • Growth factors, IGF-1, VEGF and VEGF-antibodies • Beta-blockers • Other pharmacologic interventions • Summary • References 17. How to treat hypoxic-ischemic encephalopathy with drugs Serafina Perrone, Gemma Stazzoni, Maria Luisa Tataranno, Giuseppe Buonocore Pathophysiology of HIE • Promising pharmacological interventions • Combined therapies • Conclusions • References 18. Does the best antioxidant come from the brain? Melatonin for the newborn: present and future Ignazio Barberi, Salvatore Aversa, Lucia Marseglia, Eloisa Gitto Utility of melatonin in newborns • Future prospectives • References 19. Invasive fungal infections in the nursery: the state of the art Paolo Manzoni, Elio Castagnola, Eveline Jacqz-Aigrain, Mauro Stronati, Daniele Farina Risk factors • Prevention • Treatment of neonatal invasive fungal disease: antifungal drugs • References 20. News on management of Cytomegalovirus infections Marcello Lanari, Maria Grazia Capretti, Paola Sogno Valin, Tiziana Lazzarotto Prenatal strategies to prevent CMV congenital infection • Neonatal diagnosis of CMV congenital infection • Postnatal CMV infection transmitted via mother’s milk • Neuroimaging of CMV congenital infected newborns • CMV and antiviral therapy • Conclusions • References 21. Global (pharmacological and non pharmacological) prevention of RSV infection Giovanni Corsello, Bruna Gabriele, Mario Giuffrè Respiratory syncytial virus infections • Non pharmacological prophylaxis • Pharmacological prophylaxis • Conclusions • References 22. Clinical review of pharmacologic agents for infants with severe viral bronchiolitis Corrado Moretti, Paola Papoff, Carla Cerasaro, Caterina Silvia Barbàra, Serena Salvadei, Fabio Midulla Antibiotics • Beta agonists, epinephrine and hypertonic saline • Corticosteroids • DNase • Caffeine • Surfactant • Anesthetics • Conclusions • References 23. Perinatal antiretroviral therapy Natella Y. Rakhmanina, Sahera Dirajlal-Fargo, John N. van den Anker Antiretroviral therapy during pregnancy and delivery • Neonatal antiretroviral prophylaxis • Safety of perinatal antiretroviral therapy • Conclusions • References Index |
Questo libro è anche in: